Cargando…

[(11)C]Choline PET/CT in therapy response assessment of a neoadjuvant therapy in locally advanced and high risk prostate cancer before radical prostatectomy

PURPOSE: Recent studies have shown promising results of neoadjuvant therapy in prostate cancer (PC). The aim of this study was to evaluate the potential of [(11)C]Choline PET/CT in therapy response monitoring after combined neoadjuvant docetaxel chemotherapy and complete androgen blockade in locally...

Descripción completa

Detalles Bibliográficos
Autores principales:	Schwarzenböck, Sarah M., Knieling, Anna, Souvatzoglou, Michael, Kurth, Jens, Steiger, Katja, Eiber, Matthias, Esposito, Irene, Retz, Margitta, Kübler, Hubert, Gschwend, Jürgen E., Schwaiger, Markus, Krause, Bernd J., Thalgott, Mark
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5325400/ https://www.ncbi.nlm.nih.gov/pubmed/27572317 http://dx.doi.org/10.18632/oncotarget.11653

Ejemplares similares

Categorical versus continuous circulating tumor cell enumeration as early surrogate marker for therapy response and prognosis during docetaxel therapy in metastatic prostate cancer patients
por: Thalgott, Mark, et al.
Publicado: (2015)

Long-term results of a phase II study with neoadjuvant docetaxel chemotherapy and complete androgen blockade in locally advanced and high-risk prostate cancer
por: Thalgott, Mark, et al.
Publicado: (2014)

Choline PET and PET/CT in Primary Diagnosis and Staging of Prostate Cancer
por: Schwarzenböck, S., et al.
Publicado: (2012)

Cytoreductive radical prostatectomy after chemohormonal therapy in patients with primary metastatic prostate cancer
por: Babst, Christa, et al.
Publicado: (2022)

KLK3 and TMPRSS2 for molecular lymph-node staging in prostate cancer patients undergoing radical prostatectomy
por: Lunger, Lukas, et al.
Publicado: (2020)

Radiation therapy before radical cystectomy combined with immunotherapy in locally advanced bladder cancer – study protocol of a prospective, single arm, multicenter phase II trial (RACE IT)
por: Schmid, Sebastian C., et al.
Publicado: (2020)

Neoadjuvant hormonal therapy is a feasible option in laparoscopic radical prostatectomy
por: Naiki, Taku, et al.
Publicado: (2012)

Both radiographical and pathological lymph node statuses are independent predictors for survival following neoadjuvant chemotherapy and radical cystectomy for cT3/4 or cN+ bladder cancer
por: Wagner, Julia, et al.
Publicado: (2022)

Mutant PIK3CA controls DUSP1-dependent ERK 1/2 activity to confer response to AKT target therapy
por: Sathe, A, et al.
Publicado: (2014)

Negative impact of neoadjuvant hormonal therapy on detecting biochemical recurrence after radical prostatectomy
por: Matsumoto, Kazuhiro, et al.
Publicado: (2021)

Enzalutamide (formerly MDV3100) prolongs survival in docetaxel-pretreated castration-resistant prostate cancer patients
por: Heck, Matthias M., et al.
Publicado: (2013)

Androgen deprivation therapy plus apalutamide as neoadjuvant therapy prior radical prostatectomy for patients with unresectable prostate cancer
por: Wei, Yongbao, et al.
Publicado: (2023)

Significance of Neoadjuvant Hormonal Therapy in Radical Retropubic Prostatectomy: A Retrospective Single-Surgeon Study
por: Yamamichi, Fukashi, et al.
Publicado: (2013)

Neoadjuvant androgen-deprivation therapy with radical prostatectomy for prostate cancer in association with age and serum testosterone
por: Akitake, Naoko, et al.
Publicado: (2018)

Effect of Neoadjuvant Hormonal Therapy on the Postoperative Course for Patients Undergoing Robot-Assisted Radical Prostatectomy
por: Farzat, Mahmoud, et al.
Publicado: (2023)

Radiation Therapy After Radical Prostatectomy
por: Ziada, Ali M., et al.
Publicado: (2004)

Neoadjuvant Chemohormonal Therapy before Radical Prostatectomy for Japanese Patients with High-Risk Localized Prostate Cancer
por: Sasaki, Takeshi, et al.
Publicado: (2021)

Neoadjuvant Chemohormonal Therapy in Prostate Cancer Before Radical Prostatectomy: A Systematic Review and Meta-Analysis
por: Ge, Qingyu, et al.
Publicado: (2022)

Clinical efficacy of neoadjuvant chemohormonal therapy combined with laparoscopic radical prostatectomy in high-risk Prostate Cancer
por: Zhang, Peng, et al.
Publicado: (2022)

Non-invasive assessment of inter-and intrapatient variability of integrin expression in metastasized prostate cancer by PET
por: Beer, Ambros J., et al.
Publicado: (2016)

External radiation exposure, excretion, and effective half-life in (177)Lu-PSMA-targeted therapies
por: Kurth, J., et al.
Publicado: (2018)

Analysis of risk factors for positive surgical margin after laparoscopic radical prostatectomy with and without neoadjuvant hormonal therapy
por: Wang, Fangming, et al.
Publicado: (2023)

Neoadjuvant Hormonal Therapy Preceding Radical Prostatectomy for Clinically Localized Prostate Cancer: Early Postoperative Complications and Biochemical Recurrence
por: Yang, Seung Woo, et al.
Publicado: (2011)

The prevalence and outcomes of pT0 disease after neoadjuvant hormonal therapy and radical prostatectomy in high-risk prostate cancer
por: Joung, Jae Young, et al.
Publicado: (2015)

Feasibility of Neoadjuvant Ad‐REIC Gene Therapy in Patients with High‐Risk Localized Prostate Cancer Undergoing Radical Prostatectomy
por: Kumon, Hiromi, et al.
Publicado: (2015)

Neoadjuvant hormone therapy following treatment with robotic-assisted radical prostatectomy achieved favorable in high-risk prostate cancer
por: Hou, Cheng-Pang, et al.
Publicado: (2014)

Neoadjuvant Androgen Deprivation Therapy Effects on Perioperative Outcomes Prior to Radical Prostatectomy: Eleven Years of Experiences at Ramathibodi Hospital
por: Sangkum, Premsant, et al.
Publicado: (2021)

Radiation Therapy after Radical Prostatectomy: Implications for Clinicians
por: Herrera, Fernanda G., et al.
Publicado: (2016)

Oligometastases from prostate cancer: local treatment with stereotactic body radiotherapy (SBRT)
por: Habl, Gregor, et al.
Publicado: (2017)

S6K1 and 4E-BP1 Are Independent Regulated and Control Cellular Growth in Bladder Cancer
por: Nawroth, Roman, et al.
Publicado: (2011)

Reduction in PSA messenger-RNA expression and clinical recurrence in patients with prostatic cancer undergoing neoadjuvant therapy before radical prostatectomy
por: Grasso, Marco, et al.
Publicado: (2004)

PSMA-ligand uptake can serve as a novel biomarker in primary prostate cancer to predict outcome after radical prostatectomy
por: Wang, Hui, et al.
Publicado: (2021)

Streamlined Schemes for Dosimetry of (177)Lu-Labeled PSMA Targeting Radioligands in Therapy of Prostate Cancer
por: Kurth, Jens, et al.
Publicado: (2021)

Radical prostatectomy specimens – a voice against focal therapy
por: Adamczyk, Przemysław, et al.
Publicado: (2014)

Significance of pelvic lymph node dissection during radical prostatectomy in high-risk prostate cancer patients receiving neoadjuvant chemohormonal therapy
por: Iwamura, Hiromichi, et al.
Publicado: (2022)

Neoadjuvant androgen deprivation therapy combined with abiraterone acetate in patients with locally advanced or metastatic prostate cancer: When to perform radical prostatectomy?
por: Xu, Ziyang, et al.
Publicado: (2022)

Radical Prostatectomy and Intraoperative Radiation Therapy in High-Risk Prostate Cancer
por: Marchioro, Giansilvio, et al.
Publicado: (2012)

Role of Dose Intensification for Salvage Radiation Therapy after Radical Prostatectomy
por: Beck, Marcus, et al.
Publicado: (2016)

Radical prostatectomy in locally advanced cancer – an indispensable onset of multimodal therapy?
por: Malewski, Wojciech, et al.
Publicado: (2017)

Neoadjuvant hormonal therapy for low‐risk prostate cancer induces biochemical recurrence after radical prostatectomy via increased lymphangiogenesis‐related parameters
por: Miyata, Yasuyoshi, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_ss523plbidr4nn18rmv4a8l26t